A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia

Leukemia Research

Volumn 28, Issue 4, 2004, Pages 353-357

  Giles, Francis J ^a   Cortes, Jorge E ^a   Kantarjian, Hagop M ^a   O'Brien, Susan M ^a   Estey, Elihu ^a   Beran, Miloslav ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; Cytarabine; Fludarabine; Refractory; Topotecan

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CYTARABINE; FLUDARABINE; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BACTEREMIA; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; DEATH; DIARRHEA; FEMALE; FEVER; HUMAN; INFECTION; MALE; MORTALITY; MYCOSIS; NAUSEA; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; VOMITING;

EID: 1042289343     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.08.013     Document Type: Article

References (22)

1. Gandhi V., Huang P., Plunkett W. Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias. Leuk Lymphoma. 14:1994;3-9.
2. Estey E., Plunkett W., Gandhi V.et al. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 9:1993;343-350.
3. Gandhi V., Estey E., Du M.et al. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin. Cancer Res. 3:1997;1539-1545.
4. Estey E.H., Thall P.F., Pierce S.et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± all-trans-retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 93:1999;2478-2484.
5. Estey E.H., Thall P.F., Cortes J.E.et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood. 98:2001;3575-3583.
6. Kantarjian H.M., Beran M., Ellis A.et al. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood. 81:1993;1146-1151.
7. Rowinsky E.K., Adjei A., Donehower R.C.et al. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J. Clin. Oncol. 12:1994;2193-2203.
8. Rowinsky E.K., Kaufmann S.H., Baker S.D.et al. A phase I and pharmacological study of topotecan infused over 30-min for five days in patients with refractory acute leukemia. Clin. Cancer Res. 2:1996;1921-1930.
9. Beran M., Estey E., O'Brien S.M.et al. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma. 31:1998;521-531.
10. Beran M., Kantarjian H. Topotecan in the treatment of hematologic malignancies. Semin. Hematol. 35:1998;26-31.
11. Beran M., Kantarjian H. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Semin. Hematol. 36:1999;3-10.
12. Beran M., Estey E., O'Brien S.et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J. Clin. Oncol. 17:1999;2819-2830.
13. Beran M., Shen Y., Kantarjian H.et al. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer. 92:2001;1999-2015.
14. Estey E., Kornblau S., Pierce S.et al. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood. 88:1996;756.
15. Leoni F., Ciolli S., Nozzoli C.et al. Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report. Haematologica. 86:2001;104.
16. Sonis S.T., Fey E.G. Oral complications of cancer therapy. Oncology (Huntingt). 16:2002;680-695.
17. Giles F.J., Redman R., Yazji S.et al. Iseganan HCl: a novel antimicrobial agent. Expert Opin. Investig. Drugs. 11:2002;1161-1170.
18. Ellis M., Zwaan F., Hedstrom U.et al. Recombinant human interleukin 11 and bacterial infection in patients with haemological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. Lancet. 361:2003;275-280.
19. Estey E.H., Thall P.F., Giles F.J.et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood. 99:2002;4343-4349.
20. Keith J.C. Jr., Albert L., Sonis S.T.et al. IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells. 12:1994;79-89.
21. Giles F.J., Cortes J.E., Thomas D.A.et al. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin. Cancer Res. 8:2002;2134-2141.
22. Tomkinson B, Bendele R, Giles F, et al. OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL. Leuk Res; 2003.